What the data shows
What happens when twins are diagnosed with a life-altering condition? For Jesy Nelson’s children, Emma and Bartosz, the answer is a battle against Spinal Muscular Atrophy (SMA), a severe genetic disorder that has left them facing significant mobility challenges. Emma and Bartosz were diagnosed with SMA type 1, the most severe form of the disease, with Emma’s diagnosis occurring in 2024 and Bartosz’s in 2021.
Both children received gene therapy Zolgensma through the NHS, a treatment that can halt the progression of SMA and potentially eradicate it if administered early enough. However, the late diagnosis of all four children in their family has led to likely lifelong mobility issues. This situation raises urgent questions about the adequacy of newborn screening practices in the UK.
Currently, the UK is a global outlier regarding newborn SMA screening, which is already in place in 46 countries, including the US and nearly three-quarters of Europe. The Scottish government has announced that all babies will soon be screened for SMA as part of the NHS newborn blood spot test, with a projected rollout in England by 2031. This initiative comes in light of alarming statistics: an estimated 33 UK babies will need a wheelchair due to late diagnosis of SMA.
Parents Paola and Rhys Davie, who have also faced similar challenges with their children, expressed their empathy, stating, “We know how you feel.” They understand the overwhelming emotions that accompany such diagnoses. Urszula, another parent, added, “I’m sorry you’re going through this. I remember how overwhelming it felt at the beginning.” These sentiments highlight the shared struggles of families dealing with SMA.
Paola reflected on the differences in healthcare systems, saying, “It’s awful to think that if I’d decided to give birth in Italy, we probably wouldn’t be having this conversation.” This underscores the critical importance of timely diagnosis and intervention in managing SMA.
Despite the challenges, there are moments of hope. Rhys shared, “Any moment like that when we can see she’s become stronger is incredible – we just feel so much gratitude and joy.” These small victories are vital for families navigating the complexities of SMA.
As the UK moves towards implementing newborn screening for SMA, the hope is that fewer families will face the same struggles as Jesy Nelson and others. However, details remain unconfirmed regarding the exact timeline and implementation specifics. The urgency for change in screening practices is clear, as families await a future where early diagnosis becomes the norm rather than the exception.